Making moves: Civica, Astellas, Inozyme and more announce key new hires

Civica taps COO Ned McCoy to succeed Martin VanTrieste as CEO amid push to develop low-cost insulin Civica CEO Ned McCoy Permission granted by Civica. Who: Long-time Civica chief operating officer Ned McCoy took the helm of the nonprofit generic drug company June 1, succeeding former President and CEO Martin VanTrieste. Background: McCoy brings an … Read more

Making moves: Inovio, Veru, MindMed and more announce key new hires

Listen to the article 6 min This audio is auto-generated. Please let us know if you have feedback. Veru appoints new head of its US Infectious Disease Franchise ahead of potential COVID-19 EUA Joel Batten, executive vice president of Veru’s infectious disease franchise Retrieved from Veru Inc. on May 25, 2022 Who: Joel Batten joined … Read more

A Misguided Op-Ed, a Key Report, and Why Holding the US Lead in the Life Sciences is More Important Than Ever

“As those involved in these efforts at the National Institutes of Health will readily attest, companies working with them to develop critically needed drugs and vaccines to combat COVID-19 are hardly getting a free ride. They are assuming the majority of the costs and all the risks.” Ulysses and the Sirens by JW Waterhouse: https://www.ngv.vic.gov.au/explore/collection/work/4457/ … Read more

Two Key Questions About Payer Strategies in 2022

PM360 We asked experts in dealing with payers to tell us the optimal strategies for negotiating pricing and formularies and the continued push toward value-based models. Specifically, we wanted to know: What are the keys to successful payer-pharma negotiations in 2022? What data do payers most value from pharma? How are the other needs or … Read more